ResearcherUniversity of CologneActive in the last 2 years

Sofya Tishina

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8232-496X; OpenAlex author ID A5040272702. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2026: 1 paper

Papers 1

Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. Co-author DOI 10.1038/s41467-026-73189-8 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Alexander Quaas · 1 shared paper, 2026 · strength 0.20
- Paper Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. DOI 10.1038/s41467-026-73189-8 ↗
Moritz Reese · 1 shared paper, 2026 · strength 0.20
- Paper Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. DOI 10.1038/s41467-026-73189-8 ↗
Maximilian Reichert · 1 shared paper, 2026 · strength 0.20
- Paper Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. DOI 10.1038/s41467-026-73189-8 ↗
Anna Trauzold · 1 shared paper, 2026 · strength 0.20
- Paper Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. DOI 10.1038/s41467-026-73189-8 ↗
Janine Murr · 1 shared paper, 2026 · strength 0.20
- Paper Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. DOI 10.1038/s41467-026-73189-8 ↗
Silvia von Karstedt · 1 shared paper, 2026 · strength 0.20
- Paper Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. DOI 10.1038/s41467-026-73189-8 ↗
Igor A. Astsaturov · 1 shared paper, 2026 · strength 0.20
- Paper Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. DOI 10.1038/s41467-026-73189-8 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.